Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma

Abstract

The findings of this cost-effectiveness analysis suggest that, at its current price, pembrolizumab is not a cost-effective second-line therapy for HCC in the US, with a willingness-to-pay threshold of $150 000 per QALY.